Recombinant Human FGF19 293 Cell Lysate

• Cat.No.: FGF19-6244HCL

Specification

• Description: Antigen standard for fibroblast growth factor 19 (FGF19) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: FGF19 fibroblast growth factor 19 [ Homo sapiens ]
• Official Symbol: FGF19
• Synonyms: FGF19; fibroblast growth factor 19; FGF-19
• Gene ID: 9965
• mRNA Refseq: NM_005117
• Protein Refseq: NP_005108
• MIM: 603891
• UniProt ID: O95750
• Chromosome Location: 11q13.1
• Pathway: Downstream signaling of activated FGFR, organism-specific biosystem; FGF signaling pathway, organism-specific biosystem; FGFR ligand binding and activation, organism-specific biosystem; FGFR4 ligand binding and activation, organism-specific biosystem; FRS2-mediated cascade, organism-specific biosystem; IRS-mediated signalling, organism-specific biosystem; IRS-related events, organism-specific biosystem
• Function: fibroblast growth factor receptor binding; growth factor activity; protein binding; protein tyrosine kinase activity

Reviews

01/14/2022

Top-notch protein quality! It's our go-to for reliable and reproducible results.

09/08/2020

This product simplifies our research. It's a reliable tool that we can count on.

05/11/2018

If you're in the lab, you need this product. It streamlines processes and is a lab necessity.

Q&As

How is FGF19 gene expression regulated, and what factors influence its secretion and activity in various tissues?

FGF19 expression is regulated by bile acids and other factors. Its secretion and activity are influenced by nutrient availability, signaling pathways, and interactions with bile acid receptors.

Can you discuss the potential therapeutic applications of targeting FGF19 in metabolic disorders, and what challenges exist in developing such interventions?

Targeting FGF19 holds therapeutic potential for metabolic disorders. Challenges include achieving tissue-specific effects and understanding the long-term consequences of manipulating FGF19 signaling.

Can you explain the role of FGF19 in the enterohepatic circulation of bile acids and its implications for metabolic health?

FGF19 regulates bile acid synthesis in the liver and influences the enterohepatic circulation, impacting metabolic health by modulating lipid and glucose metabolism.

What is the role of FGF19 in the regulation of gut hormone secretion, and how does this contribute to its effects on metabolic processes?

FGF19 influences gut hormone secretion, including the release of glucagon-like peptide-1 (GLP-1). This regulation contributes to its metabolic effects, such as enhanced insulin sensitivity and reduced food intake.

What is the significance of FGF19 in metabolic diseases, and how does dysregulation contribute to conditions like obesity and non-alcoholic fatty liver disease (NAFLD)?

Dysregulation of FGF19 is implicated in metabolic diseases, including obesity and NAFLD. Altered FGF19 signaling may contribute to aberrant bile acid and lipid metabolism in these conditions.